Literature DB >> 36219323

Relationships between endogenous and exogenous testosterone and cardiovascular disease in men.

Arthi Thirumalai1, Bradley D Anawalt2.   

Abstract

In this narrative review, we discuss the evidence about the controversy about the cardiovascular effects of endogenous and exogenous testosterone in men. Prospective cohort studies with follow-up of ~5-15 years generally indicate no association or a possible inverse relationship between serum endogenous testosterone concentrations and composite major cardiovascular events, cardiovascular deaths and overall mortality. Pharmacoepidemiological studies of large databases generally show no association between testosterone therapy and incident major cardiovascular events, and some pharmacoepidemiological studies demonstrate an association with decreased overall mortality. Randomized, placebo-controlled trials indicate that there is no increased incidence of overall major cardiovascular events with 1-3 years of testosterone therapy. These placebo-controlled trials have major limitations including small numbers of participants, short duration of testosterone therapy and follow-up, and lack of systematic adjudication of cardiovascular events. Overall, the evidence indicates that endogenous testosterone concentrations and testosterone therapy at physiological dosages confer no or minimal effects on the incidence of cardiovascular outcomes. There is insufficient evidence to make conclusions about testosterone therapy for patients at high risk of cardiovascular events (e.g., men with recent myocardial infarctions or stroke and men with recurrent idiopathic deep venous thromboses). In general, clinicians should avoid prescribing supraphysiological testosterone therapy to hypogonadal men or men with slightly low to low-normal serum testosterone concentrations and no identified disorder of the hypothalamus-pituitary-testicular axis because of the uncertain cardiovascular risks and the lack of proven health benefits. For most men with bona fide hypogonadism, benefits of testosterone therapy exceed the potential risk of adverse cardiovascular effects.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular risk; Myocardial infarction; Stroke; Testosterone; Venous thromboembolism

Year:  2022        PMID: 36219323     DOI: 10.1007/s11154-022-09752-7

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   9.306


  88 in total

1.  Commentary: testosterone and the metabolic syndrome: cause or consequence?

Authors:  D Aled Rees; Colin M Dayan
Journal:  Int J Epidemiol       Date:  2010-12-24       Impact factor: 7.196

Review 2.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 3.  Testosterone in women--the clinical significance.

Authors:  Susan R Davis; Sarah Wahlin-Jacobsen
Journal:  Lancet Diabetes Endocrinol       Date:  2015-09-07       Impact factor: 32.069

4.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Authors:  Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

Review 5.  Sex-Specific Physiology and Cardiovascular Disease.

Authors:  Chrisandra L Shufelt; Christine Pacheco; Marysia S Tweet; Virginia M Miller
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

6.  Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.

Authors:  Louise Lind Schierbeck; Lars Rejnmark; Charlotte Landbo Tofteng; Lis Stilgren; Pia Eiken; Leif Mosekilde; Lars Køber; Jens-Erik Beck Jensen
Journal:  BMJ       Date:  2012-10-09

Review 7.  Gender/Sex as a Social Determinant of Cardiovascular Risk.

Authors:  Adrienne O'Neil; Anna J Scovelle; Allison J Milner; Anne Kavanagh
Journal:  Circulation       Date:  2018-02-20       Impact factor: 29.690

8.  Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Authors:  Howard N Hodis; Wendy J Mack; Victor W Henderson; Donna Shoupe; Matthew J Budoff; Juliana Hwang-Levine; Yanjie Li; Mei Feng; Laurie Dustin; Naoko Kono; Frank Z Stanczyk; Robert H Selzer; Stanley P Azen
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

Authors:  Judith Hsia; Robert D Langer; Joann E Manson; Lewis Kuller; Karen C Johnson; Susan L Hendrix; Mary Pettinger; Susan R Heckbert; Nancy Greep; Sybil Crawford; Charles B Eaton; John B Kostis; Pat Caralis; Ross Prentice
Journal:  Arch Intern Med       Date:  2006-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.